The MarketWatch News Department was not involved in the creation of this content. -- Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of ...
BioVie’s stock has moved up considerably over the past 9 months in light of promising Alzheimer’s data. BioVie Day and full Phase 2 Parkinson’s trial results are scheduled for this month. BioVie has ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor ...
The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The ascites ...
DUBLIN, June 23, 2021 /PRNewswire/ -- The "Malignant Ascites Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 ...
FORT LAUDERDALE, Fla., Dec. 31, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF), a nonprofit dedicated to raising awareness, funding research, and supporting stomach cancer ...
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Martin Pharmaceuticals, a clinical-stage pharmaceutical company targeting complications of advanced liver disease, today announced that results from its DREAM ...
BASILDON, England--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has ...
Launch Offers Prolonged Puncture-free Survival and Delayed Deterioration of Quality of Life to Patients Who Are Ineligible for Systemic Anticancer Therapy This Marks Another Milestone for Pharmanovia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results